b-AP15
Based on 13 publication(s) in Google Scholar
b-AP15 is a specific inhibitor of the deubiquitinating enzymes UCHL5 and Usp14.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.05%
- CAS No.: 1009817-63-3
- 화학식: C22H17N3O6
- 분자량:419.39
-
보관:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) b-AP15
More- Redox Biol. 2026 May:92:104086. [Abstract]
- Apoptosis. 2019 Oct;24(9-10):826-836. [Abstract]
- EMBO J. 2022 Aug 16;41(16):e108791. [Abstract]
- Cancer Gene Ther. 2026 May 2. [Abstract]
- Eur J Pharmacol. 2025 Dec 5:1008:178303. [Abstract]
- Sci Rep. 2025 Jan 13;15(1):1165. [Abstract]
- FASEB J. 2021 Aug;35(8):e21800. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Chem Asian J. 2024 Sep 2:e202400824. [Abstract]
- Biochem Biophys Res Commun. 2022 Jan 15:588:147-153. [Abstract]
- Cell Physiol Biochem. 2017;42(3):965-973. [Abstract]
- bioRxiv. 2025 May 14.
- bioRxiv. 2024 August 21.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
WB
Biological Activity
UCHL5/Usp14[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
0.26 μM
Compound: 2e
|
Cytotoxicity against CEM T-lymphocytes.
Cytotoxicity against CEM T-lymphocytes.
|
[PMID: 11170648] |
| CCRF-CEM | IC50 |
0.26 μM
Compound: 2e
|
Cytotoxicity against human CEM cells
Cytotoxicity against human CEM cells
|
[PMID: 19819135] |
| CCRF-CEM | IC50 |
0.28 μM
Compound: 417
|
Antiproliferative activity against human CEM cells assessed as cell growth inhibition
Antiproliferative activity against human CEM cells assessed as cell growth inhibition
|
[PMID: 32172081] |
| HCT-116 | EC50 |
1.05 μM
Compound: b-AP15
|
Cytotoxicity in human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by FMCA analysis
Cytotoxicity in human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by FMCA analysis
|
[PMID: 31682427] |
| HL-60 | CC50 |
0.13 μM
Compound: 2c
|
Cytotoxicity against human HL60 cells in presence of RPMI1640 containing 10% fetal bovine serum by trypan blue exclusion test
Cytotoxicity against human HL60 cells in presence of RPMI1640 containing 10% fetal bovine serum by trypan blue exclusion test
|
[PMID: 17499885] |
| HSC-2 | CC50 |
0.094 μM
Compound: 2c
|
Cytotoxicity against human HSC2 by MTT method
Cytotoxicity against human HSC2 by MTT method
|
[PMID: 17499885] |
| HSC-4 | CC50 |
0.56 μM
Compound: 2c
|
Cytotoxicity against human HSC4 cells by MTT method
Cytotoxicity against human HSC4 cells by MTT method
|
[PMID: 17499885] |
| L1210 | IC50 |
0.28 μM
Compound: 417
|
Antiproliferative activity against mouse L1210 cells assessed as cell growth inhibition
Antiproliferative activity against mouse L1210 cells assessed as cell growth inhibition
|
[PMID: 32172081] |
| L1210 | IC50 |
0.42 μM
Compound: 2e
|
Cytotoxicity against murine L1210 cells.
Cytotoxicity against murine L1210 cells.
|
[PMID: 11170648] |
| L1210 | IC50 |
0.42 μM
Compound: 2e
|
Cytotoxicity against mouse L1210 cells
Cytotoxicity against mouse L1210 cells
|
[PMID: 19819135] |
| L1210 | IC50 |
2.77 μM
Compound: 2e
|
Inhibitory effect on the biosyntheses of DNA in murine L1210 cells.
Inhibitory effect on the biosyntheses of DNA in murine L1210 cells.
|
[PMID: 11170648] |
| L1210 | IC50 |
3.21 μM
Compound: 2e
|
Inhibitory effect on the biosyntheses of protein in murine L1210 cells.
Inhibitory effect on the biosyntheses of protein in murine L1210 cells.
|
[PMID: 11170648] |
| L1210 | IC50 |
5.73 μM
Compound: 2e
|
Inhibitory effect on the biosyntheses of RNA in murine L1210 cells.
Inhibitory effect on the biosyntheses of RNA in murine L1210 cells.
|
[PMID: 11170648] |
| MOLT-4 | IC50 |
0.15 μM
Compound: 2e
|
Cytotoxicity against human Molt4/C8 cells
Cytotoxicity against human Molt4/C8 cells
|
[PMID: 19819135] |
| P388 | IC50 |
0.05 μM
Compound: 2e
|
Cytotoxicity against murine P388 cells.
Cytotoxicity against murine P388 cells.
|
[PMID: 11170648] |
| P388 | IC50 |
0.28 μM
Compound: 417
|
Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition
Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition
|
[PMID: 32172081] |
Purified 19S proteasomes (5 nM) are treated with indicated concentrations of b-AP15 and DUB activity is determined by detectionof Ub-AMC cleavage. The IC50 value (2.1±0.411 μM) is determined from log concentration curves in Graph Pad Prism using non linear regression analysis. b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14), resulting in accumulation of polyubiquitin. b-AP15 induced tumor cell apoptosis that is insensitive to TP53 status and overexpression of the apoptosis inhibitor BCL2[1]. The ability of b-AP15 is determined to inhibit proteasome deubiquitinase activity using Ub-AMC as the substrate. An IC50 of 16.8±2.8 μM is observed[2]. b-AP15 is a specific USP14 and UCHL5 inhibitor, which blocks growth and induces apoptosis in MM cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1009817-63-3
-
Appearance Solid
-
분자량 419.39
-
화학식 C22H17N3O6
-
Color Light yellow to yellow
-
SMILES
O=C1/C(CN(C(C=C)=O)C/C1=C\C2=CC=C([N+]([O-])=O)C=C2)=C/C3=CC=C([N+]([O-])=O)C=C3
-
Synonyms
NSC 687852
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [Abstract]2026 May:92:104086. PMID: 41844497
b-AP15 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]
Immunoblot analysis of target proteins in sorafenib-resistant 769-P and A549 cells following 24 h treatment with specific deubiquitinase inhibitors. ML-323: 10 μM, GSK2643943A: 10 μM, XL177A: 10 μM, Spautin-1: 10 μM, IU1: 10 μM, AZ1: 10 μM, MF-094: 10 μM, LDN-57444: 10 μM, TCID: 10 μM, PR-619: 10 μM, BAY11-7082: 10 μM, EOAI3402143: 2.5 μM, ML364: 10 μM, b-AP15: 0.5 μM.
-
Apoptosis
Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma. [Abstract]2019 Oct;24(9-10):826-836. PMID: 31342239 -
EMBO J
USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII. [Abstract]2022 Aug 16;41(16):e108791. PMID: 35811497 -
Cancer Gene Ther
b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling. [Abstract]2026 May 2. PMID: 42069980
b-AP15 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2026 May 2. [Abstract]
CCK8 cell viability analysis of HNSCC cell lines treated with increasing doses of b-AP15 and/or TRAIL for 48 h. Values below the combination are Combination Indices (CI) as described in the text.
b-AP15 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2026 May 2. [Abstract]
Colony formation assay of HNSCC cell lines treated with b-AP15 (250 nM) and/or TRAIL (50 ng/mL) for 24 h. Representative images are shown with quantification below.
b-AP15 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2026 May 2. [Abstract]
Annexin V analysis of HNSCC cell lines after treated with b-AP15 (250 nM) and/or TRAIL (50 ng/mL) for 24 and 48 h.
b-AP15 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2026 May 2. [Abstract]
Representative western blot of the expression of DR4/TRAILR1 and DR5/TRAILR2 in HNSCC cell lines treated with increasing doses of b-AP15 for 24 h. GAPDH was used as a loading control.
b-AP15 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2026 May 2. [Abstract]
Flow cytometry analysis of DR4/TRAILR1 and DR5/TRAILR2 expression in HNSCC cell lines treated with increasing doses of b-AP15 for 24 h.
b-AP15 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2026 May 2. [Abstract]
Flow cytometry analysis ROS in HNSCC cell lines treated with increasing doses of b-AP15 (0-1000 nM) for 24 h. The fluorescent probe DCFH-DA was added to cells for the detection of ROS.
-
Eur J Pharmacol
Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling. [Abstract]2025 Dec 5:1008:178303. PMID: 41183585 -
Sci Rep
Enhancing proteasome activity by NMDAR antagonists explains their therapeutic effect in neurodegenerative and mental diseases. [Abstract]2025 Jan 13;15(1):1165. PMID: 39805913 -
FASEB J
2021 Aug;35(8):e21800. PMID: 34324733 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Chem Asian J
Selective Protein Degradation through Tetrazine Ligation of Genetically Incorporated Unnatural Amino Acids. [Abstract]2024 Sep 2:e202400824. PMID: 39221720 -
Biochem Biophys Res Commun
The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. [Abstract]2022 Jan 15:588:147-153. PMID: 34954522 -
Cell Physiol Biochem
The Deubiquitinating Enzyme USP14 Regulates Leukemic Chemotherapy Drugs-Induced Cell Apoptosis by Suppressing Ubiquitination of Aurora Kinase B. [Abstract]2017;42(3):965-973. PMID: 28662510 -
-
용액&용해도
DMSO : 20 mg/mL (47.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.96 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
For deubiquitinase inhibition assays, 19S regulatory particle (5 nM), 26S (5 nM) UCH-L1 (5 nM), UCH-L3 (0.3 nM), USP2CD (5 nM) USP7CD (5 nM) USP8CD (5 nM) or BAP1 (5 nM) is incubated with DMSO or b-AP15 and monitored the cleavage of ubiquitin-AMC (1,000 nM) using a Wallac VICTOR Multilabel counter or a Tecan Infinite M1000 equipped with 380 nm excitation and 460 nm emission filters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell viability is monitored by either the fluorometric microculture cytotoxicity assay or the MTT assay. For the MTT assay, cells are seeded into 96-well flat-bottomed plates overnight and exposed to drugs, using DMSO as the control. At the end of incubations, 10 µl of a stock solution of 5 mg/mL MTT is added into each well, and the plates are incubated 4 hours at 37°C. Formazan crystals are dissolved with 100 µL 10% SDS/10 mM HCl solution overnight at 37°C. Absorbance is measured using an enzyme-linked immunosorbent assay (ELISA) plate reader at 590 nm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
For the squamous carcinoma model, 1×106 FaDu cells are subcutaneously injected into the right rear flank of female SCID mice. Tumor growth is measured by the formula length×width2×0.44. When tumors have grown to a size of approximately 200 mm3 (defined as day 0), mice are randomized to receive either vehicle (n=10) or b-AP15 (n=15) at 5 mg per kg of body weight by daily subcutaneous injection. For the colon carcinoma model, we subcutaneously injected 2.5×106 HCT-116 colon carcinoma cells overexpressing Bcl2 into the right flank of female nude mice. We treated mice with 5 mg of b-AP15 per kg of body weight by intraperitoneal injection. For the lung carcinoma model, we subcutaneously injected 2×105 LLC cells into the right rear flank of female C57/B6 mice. When tumors had grown to a size of approximately 50 mm3 (defined as day 0), we randomized mice to receive either vehicle (n=4) or b-AP15 (n=4) at 5 mg per kg of body weight intraperitoneally, with a treatment cycle consisting of 2 d of treatment followed by 2 d of rest (2 d on, 2 d off) for 2 weeks.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
순도&문서
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. D'Arcy P, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011 Nov 6;17(12):1636-40. [Content Brief]
[2]. Wang X, et al. The 19S Deubiquitinase Inhibitor b-AP15 is Enriched in Cells and Elicits Rapid Commitment to Cell Death. Mol Pharmacol. 2014 Jun;85(6):932-45. [Content Brief]
[3]. Tian Z, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30;123(5):706-16. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3844 mL | 11.9221 mL | 23.8442 mL | 59.6104 mL |
| 5 mM | 0.4769 mL | 2.3844 mL | 4.7688 mL | 11.9221 mL | |
| 10 mM | 0.2384 mL | 1.1922 mL | 2.3844 mL | 5.9610 mL | |
| 15 mM | 0.1590 mL | 0.7948 mL | 1.5896 mL | 3.9740 mL | |
| 20 mM | 0.1192 mL | 0.5961 mL | 1.1922 mL | 2.9805 mL | |
| 25 mM | 0.0954 mL | 0.4769 mL | 0.9538 mL | 2.3844 mL | |
| 30 mM | 0.0795 mL | 0.3974 mL | 0.7948 mL | 1.9870 mL | |
| 40 mM | 0.0596 mL | 0.2981 mL | 0.5961 mL | 1.4903 mL |
b-AP15 Related Classifications
HY-13989 Related Classifications
Powered by Bioz